Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $81.33

Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $81.33.

Several equities analysts have issued reports on the company. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, December 16th.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. SG Americas Securities LLC acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $532,000. Assenagon Asset Management S.A. bought a new stake in Keros Therapeutics during the 2nd quarter worth about $1,118,000. Bank of New York Mellon Corp boosted its stake in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Keros Therapeutics by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock valued at $1,903,000 after acquiring an additional 7,111 shares in the last quarter. Finally, Arizona State Retirement System increased its position in shares of Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

KROS opened at $17.03 on Wednesday. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The firm has a market cap of $689.83 million, a price-to-earnings ratio of -3.27 and a beta of 1.20. The firm’s 50-day simple moving average is $54.97 and its 200-day simple moving average is $51.59.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue was up 4750.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.33) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.